Status:
UNKNOWN
A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Lymph Node Metastases
Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
NA
Brief Summary
In the previous study, the investigator established a predictive model for non-sentinel lymph node involvement in early breast cancer (cT1-2cN0, 1-2 SLNs involvement). To validation the clinical value...
Detailed Description
In the previous study, a predictive model for non-sentinel lymph node involvement in early breast cancer (cT1-2cN0, 1-2 SLNs involvement) was established. This model was designed for predicting the st...
Eligibility Criteria
Inclusion
- the test group should be in accordance with the pathological diagnosis of breast cancer, the clinical stage of breast cancer (stage cTis, cI, cII and cT3N1M0), the initial treatment to receive surgical treatment. Complete preoperative clinical diagnosis data, including the ipsilateral axillary lymph node CEUS data and peripheral blood sample; The negative-control group should comply with the pathological diagnosis, breast adenosis, fibrocystic lesions, breast cysts and other benign lesions, with complete preoperative clinical data, also including ipsilateral axillary lymph node CEUS data and peripheral blood sample
Exclusion
- metastatic breast cancer, inflammatory breast disease, surgery without lymph node staging
- pregnancy or lactation
- patients with hematopoietic system disease or cancer, autoimmune diseases
- preservation of substandard peripheral blood samples.
Key Trial Info
Start Date :
October 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
388 Patients enrolled
Trial Details
Trial ID
NCT03280134
Start Date
October 15 2018
End Date
June 1 2020
Last Update
June 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022